Treatment options for children with hemophilia A have expanded with the FDA approval of Bayer's Jivi antihemophilic factor (recombinant), PEGylated-aucl for the treatment of pediatric patients between ...

The FDA has extended its approval of Jivi to cover the therapy's use in children with hemophilia A ages 7 years and older.

The company said the discontinuation was due to several reasons,” Reuters news service reported, “including limited interest ...

Bayer’s Jivi is a factor VIII replacement therapy that has been engineered with a compound that allows for less frequent dosing. It is now indicated for patients 7 years of age and older.

The approval in previously treated pediatric patients was based on data from the Alfa-PROTECT and PROTECT Kids studies.